We found that glioblastoma, ovarian, and breast cancer patients with higher MXD3 expressions were resistant to chemotherapies, while colorectal cancer patients with higher MXD3 expression benefited more from chemotherapies than cohorts with lower expression (Fig. 7B). Here, MXD3 is linked to glioblastoma.